At a glance
ClinicalIndex Comparison Record- ✓Age 6–12 months for vaccination arm (cohort 1A)
- ✓Age 3–12 months for natural infection arm (cohort 1B)
- ✓Age 13–35 months for either vaccination or natural infection (cohort 2)
- ✓Age 36 months to 5 years for either vaccination or natural infection (cohort 3)
- ✕Immunosuppression from underlying illness, HIV, or primary immunodeficiency syndrome
- ✕Active neoplastic disease
- ✕Use of immunosuppressive medications currently or within past year, or chronic (>2 weeks) oral or inhaled steroid use
- ✕Asthma requiring chronic controller medication
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Understanding How the Initial Encounter With Influenza Virus Poises Children for Protective Immunity
In Brief
A clinical study evaluating Seasonal IIV 0.25 mL dose, Natural influenza infection, and 1 other intervention for Influenza. Completed, enrolled 134 participants across 1 site.
Detailed Summary
This study evaluates how different methods of early exposure to influenza (natural infection, live attenuated influenza vaccination, inactivated influenza vaccination) initially stimulate immunity and poise the immune system to respond to a future challenge with the inactivated influenza vaccine.
Study Details
Timeline
Interventions
Fluzone (Sanofi Pasteur) 0.25 mL administered intramuscularly to children between 6 and 35 months of age
Children enrolled on presentation to their primary care provider with a natural influenza infection
Fluzone (Sanofi Pasteur) 0.25 mL administered intramuscularly to children between 6 and 35 months of age